Cancer Cure News 2017: SoKor Researchers Posit Use of Acupuncture to Cure Cancer
A South Korean research team has recently presented a new revolutionary procedure to treat cancer.
According to reports, Professor Su-Il In and his group from the Department of Energy Science and Engineering of Daegu Gyeongbuk Institute of Science and Technology (DGIST) may have discovered a way to cure different types of cancer, including colorectal. The procedure is said to be a combination of nanotechnology and oriental medicine technology through the use of acupuncture.
Professor In's team worked with DGIST's Dr. Eunjoo Kim of the Companion Diagnostics & Medical Technology Research Group and Daegu Haany University's Professor Bong-Hyo Lee and his aides from the College of Oriental Medicine. They discovered that through acupuncture, the molecular biologic indicators related to anticancer effects changed. The study is reportedly the first in the world to use acupuncture needles that employ nanotechnology.
Get Our Latest News for FREE
In oriental medicine, acupuncture has been used to treat musculoskeletal disorders and provide pain relief. Professor In's team of researchers has developed nanoporous needles with microscopic holes by applying simple electrochemical nanotechnology. When tested on laboratory rats, they discovered that the periodic treatment resulted in a much lower occurrence of abnormal vascular clusters, a sign of colorectal cancer.
"This research, which combines nanotechnology and oriental medicine technology, is a scientific study that shows the possibility of using acupuncture as a method to treat severe diseases such as cancer. From now on, I will challenge the development of a new medical market by conducting a follow-up convergence study that identifies the potential benefits and efficacy of acupuncture," Professor In explained.
Meanwhile, the US Food and Drug Administration recently approved a new radical therapy for cancer patients. Yescarta by Kite Pharma is a treatment that reportedly involves the rebooting a patient's own immune cells to kill cancer. The FDA permitted its use to adults patients, with aggressive forms of a blood cancer like non-Hodgkin's lymphoma, who have undergone two failed chemotherapy sessions.
